Literature DB >> 18211931

A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats.

A Bhatwadekar1, J V Glenn, J L Figarola, S Scott, T A Gardiner, S Rahbar, A W Stitt.   

Abstract

BACKGROUND: Diabetic retinopathy is associated with accumulation of advanced glycation end products in the retinal microvasculature. LR-90 is an effective multistage inhibitor of advanced glycation with renoprotective and anti-inflammatory properties. AIM: To explore the role of LR-90 in the progression of experimental diabetic retinopathy.
METHODS: Streptozotocin-induced diabetic Sprague-Dawley rats were treated with LR-90 (50 mg/l in drinking water) for up to 32 weeks. At the end of the study, eyes were enucleated and subjected to trypsin digestion and staining with light green/haematoxylin. Acellular capillaries and pericytes were quantified in random fields using light microscopy.
RESULTS: In the LR-90-treated diabetic animals, acellular capillary numbers were reduced to 1.63 (0.20) from 2.58 (0.49) (p<0.05) in diabetic controls. LR-90 treatment also restored the pericyte deficit from 18.12 (0.98) in diabetic rats to 24.19 (0.76) (p<0.001).
CONCLUSION: These findings show that LR-90 can effectively inhibit important lesions of diabetic retinopathy. This agent has potential for preventing retinopathy in patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18211931     DOI: 10.1136/bjo.2007.127910

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  21 in total

Review 1.  Targeting advanced glycation with pharmaceutical agents: where are we now?

Authors:  Danielle J Borg; Josephine M Forbes
Journal:  Glycoconj J       Date:  2016-07-09       Impact factor: 2.916

Review 2.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

Review 3.  Cell-based therapies for diabetic retinopathy.

Authors:  Lynn C Shaw; Matthew B Neu; Maria B Grant
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

4.  Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes.

Authors:  Cristiano P Vieira; Seth D Fortmann; Masroor Hossain; Ana Leda Longhini; Sandra S Hammer; Bright Asare-Bediako; David K Crossman; Micheli S Sielski; Yvonne Adu-Agyeiwaah; Mariana Dupont; Jason L Floyd; Sergio Li Calzi; Todd Lydic; Robert S Welner; Gary J Blanchard; Julia V Busik; Maria B Grant
Journal:  JCI Insight       Date:  2020-07-09

5.  Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis.

Authors:  S Satheesan; J L Figarola; T Dabbs; S Rahbar; R Ermel
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

6.  LR-90 prevents methylglyoxal-induced oxidative stress and apoptosis in human endothelial cells.

Authors:  James L Figarola; Jyotsana Singhal; Samuel Rahbar; Sanjay Awasthi; Sharad S Singhal
Journal:  Apoptosis       Date:  2014-05       Impact factor: 4.677

7.  Diabetes-related adduct formation and retinopathy.

Authors:  Alan W Stitt; Timothy M Curtis
Journal:  J Ocul Biol Dis Infor       Date:  2011-12-28

8.  Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products.

Authors:  T M Curtis; R Hamilton; P-H Yong; C M McVicar; A Berner; R Pringle; K Uchida; R Nagai; S Brockbank; A W Stitt
Journal:  Diabetologia       Date:  2010-11-30       Impact factor: 10.122

9.  Conditional Deletion of Bmal1 Accentuates Microvascular and Macrovascular Injury.

Authors:  Ashay D Bhatwadekar; Eleni Beli; Yanpeng Diao; Jonathan Chen; Qianyi Luo; Alpha Alex; Sergio Caballero; James M Dominguez; Tatiana E Salazar; Julia V Busik; Mark S Segal; Maria B Grant
Journal:  Am J Pathol       Date:  2017-04-19       Impact factor: 4.307

10.  CX3CR1 deficiency accelerates the development of retinopathy in a rodent model of type 1 diabetes.

Authors:  Eleni Beli; James M Dominguez; Ping Hu; Jeffrey S Thinschmidt; Sergio Caballero; Sergio Li Calzi; Defang Luo; Sumathi Shanmugam; Tatiana E Salazar; Yaqian Duan; Michael E Boulton; Susanna Mohr; Steven F Abcouwer; Daniel R Saban; Jeffrey K Harrison; Maria B Grant
Journal:  J Mol Med (Berl)       Date:  2016-06-25       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.